GlaxoSmithKline Pharmaceuticals will be discontinuing supply of Digibind from the 1st March 2011. This is an irrecoverable decision because the manufacturing site is closing and impacts on all Digibind markets.
An alternative product (Digifab) is available on a named patient basis from Beacon Pharmaceuticals Ltd. Digifab has been on the market in the US for several years.
Orders can be faxed to Beacon Pharmaceuticals (details below) or preferably sent by e-mail to
Stacey Sargant on email@example.com
Beacon Pharmaceuticals Ltd,
News posted on February 10, 2011
Web site design and development by Flo Web Design